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Analysis of rare copy number variation in
absence epilepsies
ABSTRACT
Objective: To identify shared genes and pathways between common absence epilepsy (AE) sub-
types (childhood absence epilepsy [CAE], juvenile absence epilepsy [JAE], and unclassified
absence epilepsy [UAE]) that may indicate common mechanisms for absence seizure generation
and potentially a diagnostic continuum.
Methods: We used high-density single-nucleotide polymorphism arrays to analyze genome-wide
rare copy number variation (CNV) in a cohort of 144 children with AEs (95 CAE, 26 UAE, and
23 JAE).
Results: We identified CNVs that are known risk factors for AE in 4 patients, including 3x
15q11.2 deletion. We also expanded the phenotype at 4 regions more commonly identified in
other neurodevelopmental disorders: 1p36.33 duplication, 1q21.1 deletion, 22q11.2 duplica-
tion, and Xp22.31 deletion and duplication. Fifteen patients (10.5%) were found to carry rare
CNVs that disrupt genes associated with neuronal development and function (8 CAE, 2 JAE,
and 5 UAE). Four categories of protein are each disrupted by several CNVs: (1) synaptic vesicle
membrane or vesicle endocytosis, (2) synaptic cell adhesion, (3) synapse organization and motility
via actin, and (4) gap junctions. CNVs within these categories are shared across the AE subtypes.
Conclusions: Our results have reinforced the complex and heterogeneous nature of the AEs and
their potential for shared genetic mechanisms and have highlighted several pathways that may be
important in epileptogenesis of absence seizures. Neurol Genet 2016;2:e56; doi: 10.1212/
NXG.0000000000000056
GLOSSARY
AE5 absence epilepsy; BDNF5 brain-derived neurotrophic factor; CAE5 childhood absence epilepsy; CNV5 copy number
variation; GGE 5 genetic generalized epilepsy; GO 5 Gene Ontology; GOI 5 gene of interest; ID 5 intellectual disability;
JAE 5 juvenile absence epilepsy; LTP 5 long-term potentiation; MR 5 mental retardation; SNP 5 single-nucleotide poly-
morphism; UAE 5 unclassified absence epilepsy.
Absence seizures, abrupt and brief epileptic disruptions of consciousness associated with spike-
and-wave discharges on EEG, are predominant in 2 pediatric genetic generalized epilepsies
(GGEs): childhood absence epilepsy (CAE) and juvenile absence epilepsy (JAE). Debate con-
cerning the most appropriate diagnostic criteria means many patients receive unclassified
absence epilepsy (UAE) diagnosis.1 UAE could reflect a syndromic continuum between CAE
and JAE or could be a distinct group (or groups) with different prognoses and potentially
distinct pathophysiologic mechanisms.
The complex genetic basis of CAE and JAE remains largely undiscovered; rare mutations and
susceptibility alleles in predominantly GABAA receptors and voltage-activated calcium channels
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have been identified to date.2,3 Multiple GGE
subsyndromes can occur in one family, which
indicates a close genetic relationship between
the AEs, consistent with an oligogenic model
of inheritance.4 AEs are often studied apart,
but some investigations show common genetic
causality,5 whereas others identify factors that
are not shared.6 Recurrent microdeletions at
15q11.2, 15q13.3, and 16p13.11 are strongly
associated risk factors for GGEs, occurring in
0.5% to 1% of patients.7 Around 8% of pa-
tients with GGE also carry rare gene-disrupting
copy number variations (CNVs), with enrich-
ment for genes previously implicated in neuro-
developmental disorders, including deletions of
RBFOX1 and NRXN1.8–11
We identify novel rare CNVs in a cohort of
classical CAE and JAE cases, as well as UAEs
with atypical seizure patterns or age at onset.
The identification of shared genes and path-
ways could indicate common mechanisms for
absence seizure generation.
METHODS Study participants and phenotyping. Unre-
lated patients of European ancestry, previously recruited for 2
studies of GGEs from 1997 to 2007, were ascertained from
hospitals across Europe: United Kingdom, Greece, France,
Germany, Austria, the Netherlands, Denmark, Sweden, Finland,
and Italy, as reported previously.1,12 In patients with absences but
without notable myoclonus, we used an adapted version of the
International League Against Epilepsy 1989 Criteria to classify as
CAE, JAE, and UAE (table e-1 at Neurology.org/ng) based on
age at onset, seizure frequency, and EEG findings.1,13 The criteria
require “normal background” EEG, which was interpreted as age-
appropriate normal posterior dominant rhythm during
wakefulness (sleep EEG was not specifically evaluated for this
study). Interictal fragments of generalized or bilateral symmetric
spike-and-wave discharges and some isolated focal discharges are
commonly seen in AEs and were not considered an exclusion
criterion for our study.
To maximize inclusion of relevant patients, criteria were adap-
ted as follows: (1) very frequent absences (several times a day, pyk-
nolepsy) were considered an inclusion criterion for CAE and an
exclusion criterion for JAE, which aided classification of children
in the intermediate age range; (2) patients ,4 years who would
otherwise meet the definition for CAEwere included as CAE in our
analysis, as their clinical course often resembles that of classical
CAE14; and (3) patients with focal neurologic deficits were excluded
from analysis. Although grossly normal cognitive development is
presumed in CAE and JAE, patients with comorbid developmental
delay were included as UAE.
This study was a retrospective analysis of previously recruited
cohorts; full reports of MRIs and EEGs of some patients were not
available for reanalysis in this study (table 1). Patients underwent
EEG in their clinical workup and had syndromic diagnoses of a
GGE with predominant absences based on these1,12; further anal-
ysis of phenotypic information presented in this study was used to
consistently classify patients into subtypes, rather than question
the GGE diagnosis. Any genetic testing performed as part of
clinical care was not accessed.
Standard protocol approvals, registrations, and patient
consents. Individuals from the United Kingdom were recruited
into a previous study as detailed in references 1 and 15 (ethics
approval numbers 835/5/97 and 98-334, respectively). Written
informed consent was obtained from all participants and/or their
parents. Other UK individuals and those with European ancestry
from Greece, France, Germany, Austria, the Netherlands,
Denmark, Sweden, Finland, and Italy, collected as part of the sec-
ond study detailed here,12 had age-appropriate written informed
consent obtained. Full protocol approval was obtained from local
research ethics committees and/or participating institutions as
appropriate.
Genotyping and copy number variant detection. High-
density single-nucleotide polymorphism (SNP) genotyping
arrays (HumanCoreExome-12 v1-0; Illumina, San Diego, CA)
were used to detect the presence of CNVs from genomic DNA.
Arrays were processed according to the manufacturer’s
instructions. To minimize false-positives, CNVs were called
using the Nexus Copy Number package (BioDiscovery Inc,
Hawthorne, CA) from signal intensity data after preprocessing
in Illumina GenomeStudio Software. In Nexus, systematic array
correction files were used with the linear correction model to
correct for GC bias, and a significance threshold of 1 3 1027
was applied. The SNP-FAST2 Segmentation algorithm was used
for analysis, with homozygous frequency threshold at 0.95,
hemizygous loss threshold at 20.23, and single copy gain at
0.13 for the log R ratio. A total of 184 samples were processed
on the arrays. Samples were removed from the project if they
had 1 or more of the following: a ,95% call rate (0 samples),
a probe-to-probe variability (quality) of .0.1 (15 samples), a sex
mismatch (0 samples), and .100 CNVs (34 samples), leaving n 5
144. To avoid false-positives, only variants that contained .12
consecutive altered SNP probes and that were .20 kb in size were
analyzed. CNVs showing .90% coverage of variants of a frequency
of $0.1% of the same type, reported in the Database of Genomic
Variants (http://dgv.tcag.ca/dgv/app/home), using array comparative
genomic hybridization or SNP arrays, were considered copy number
polymorphisms and were excluded from further analysis (i.e., CNVs
reported in this study are designated as “rare”). CNVs that did not
overlap exons of a gene were also excluded. The potential for
pathogenicity was based on gene content/disruption, CNV size,
frequency, and previous association of genes or regions with
epilepsy and related neurologic conditions. Gene products were
annotated for Gene Ontology (GO) categories within biological
processes and molecular functions using the Gene Ontology
Consortium Web tool at http://geneontology.org/.
Validation of copy number variants. CNV validation was
performed with real-time quantitative PCR using the Qiagen
(Hilden, Germany) Type-it CNV Sybr Green Kit according to
the manufacturer’s instructions. Reactions were performed in
10.4-mL volumes in the ABI PRISM 7900 system (Applied
Biosystems, Foster City, CA). PCR conditions were 5 minutes
at 95°C followed by 35 cycles of 30 seconds of denaturation at
95°C and 30 seconds of annealing/extension at 60°C. All samples
were run in triplicate. The PCR efficiency of each primer pair was
checked over a dilution series of DNA for comparability with the
proprietary reference assay of a multicopy gene. The DDCT
method of relative quantification was used, and the ratio (R) of
the copy number change of the gene of interest (GOI) in the case
sample was compared with the control sample calculated using
R5 22DDCT. If R. 1, the copy number of the GOI was higher in
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the case than in the control; if R, 1, the copy number was lower
in the case.
RESULTS We studied genome-wide CNV in a
cohort of 144 European patients with AEs. Of
these, 95 (66%) had CAE, 26 (18%) had UAE,
and 23 (16%) had JAE. All CNVs called are listed
in table e-2. We identified recurrent CNV hotspots
that are known risk factors for GGEs in 4
individuals (tables 1 and 2). At the GGE hotspot
15q11.2, there were 3 deletions: 1 in a patient with
CAE, 1 in a patient with JAE, and 1 in a patient with
UAE. We also noted a 15q11.2 duplication in a
patient with CAE. We recorded a smaller duplication
Table 1 Clinical characteristics of patients with absence epilepsy with recurrent risk factor or rare potential risk factor CNVs
Patient ID (sex)
Diagnosis (age





Ictal EEG and activation
procedures
C382 (F) JAE (9-GCTS) GTCS, absences, very rare
myoclonic jerks
None PSW Response to hyperventilation not
listed
361202 (M) CAE (8) Typical absences NA None seen 3-Hz GSW on hyperventilation
C626 (F) JAE (14) Absences; initially GTCS,
nonepileptic seizuresa
None Atypical GSW: irregular
spikes and sharp waves
No ictal EEG, no response to
hyperventilation; PPR unknown
371201 (F) CAE (7) Typical absences NA Brief generalized PSW 3-Hz GSW on hyperventilation
367202 (F) UAE (7) Atypical absences (.1-min duration) NA None seen No ictal EEG
C215 (M) CAE (7) Typical absences Yes (2nd) None seen 3-Hz GSW on hyperventilation
C457 (F) CAE (7) Typical absences None None seen 3-Hz GSW on hyperventilation,
several spontaneous absences
C485 (F) CAE (8) Typical absences, pyknoleptic
presentation; GTCS onset 14 y
None GSW with right emphasis GSW with right emphasis; GSW on
hyperventilation; absence during
EEG
424004 (F) UAE (7) Atypical absences (degree of
postural tone loss)
NA NA for review NA for review
C516 (M) JAE (9-GTCS) GTCS; absence onset in teens None Atypical GSW PPR present; no absence during EEG
667201 (M) CAE (9) Typical absences NA None seen 3-Hz GSW and PSW on
hyperventilation
369201 (F) CAE (6) Typical absences NA None seen 3-Hz GSW
341203 (F) UAE (4) Typical absencesb NA None seen 3-Hz GSW on hyperventilation
357201 (M) UAE (1) Typical absencesc Yes (1st) GSW 3-Hz GSW on hyperventilation
397201 (M) CAE (3) Typical absences, GTCS NA GSW NA for review
C329 (M) CAE (7) Typical absences (until 21 y),
GTCS in teens
None NA for review “Typical centrencephalic petit mal
epilepsy” on EEG report
C8 (F) UAE (7) Atypical absences, initially 2–3/
day; aura later reported
Yes (2nd) Generalized PSW,
bilateral temporal
sharp waves
PSW with aura later reported; no
absence during EEG
717201 (F) CAE (10) Typical absences NA None seen 3-Hz GSW
C72 (M) UAE (6) Atypical absences (atypical spike-
wave on hyperventilation pause)
NA Atypical spike-wave Bursts of slow waves with few
associated spikes with pause in
hyperventilation
349201 (M) CAE (6) Typical absences NA None seen 2.5-Hz SW on hyperventilation and
photosensitive
C451 (M) CAE (4) Atypical absences Yes (1st) GSW No ictal EEG, no response to
hyperventilation
830201 (F) CAE (9) Typical absences NA Reported focal
abnormality, NA for
review
3-Hz GSW on hyperventilation
C454 (M) JAE (11) Typical absences daily and in
runs; 1 GTCS age 11y
None PSW; focal right-sided
discharge
PSW; right-sided discharge
Abbreviations: CAE 5 childhood absence epilepsy; CNV 5 copy number variation; GCTS 5 generalized tonic-clonic seizures; GSW 5 generalized spike-
wave discharges; JAE 5 juvenile absence epilepsy; NA 5 not available; PSW 5 polyspike-wave discharges; UAE 5 unclassified absence epilepsy.
Typical absences: brief interruptions of consciousness (4–20 seconds) with EEG ictal GSW at 3 Hz. Family history refers to family history of any epileptic
seizure disorder but does not include febrile seizures. Under the “Seizures” and “Ictal EEG” columns, no GTCS, no myoclonus, no febrile seizures (FS), and no
photoparoxysmal response (PPR) is implied unless stated otherwise. Although patients underwent EEG as part of their initial clinical workup and diagnosis,
not all full EEGs or EEG reports were available for review; this is indicated in the table above.
aMRI: no epileptogenic lesion but scattered white matter change and cerebellar atrophy.
bAlso has developmental delay and FS.
cMRI reported abnormal but no epileptogenic lesion; measles at 10 months; FS provoked by measles, mumps, and rubella vaccine; developmental delay.
Neurology: Genetics 3
ª 2016 American Academy of Neurology. Unauthorized reproduction of this article is prohibited.
in the patient with JAE (C626) within a second GGE
hotspot, 15q13.3, including the candidate gene
CHRNA7. CNVs at 4 further recurrent CNV
hotspots, more commonly recorded in other
neurodevelopmental disorders, were also identified in
this study: a distal 1p36.3 duplication including the
infantile spasms candidate gene KLHL1716 (JAE), a
1q21.1 deletion (CAE), a 2.8-Mb duplication at
22q11.2 (CAE), and 1 deletion and 1 duplication at
Xp22.31 (CAE/JAE). Of note, 1 patient with JAE,
C626, carries 3 of these recurrent CNVs (tables
1 and 2).
Fifteen patients (11%) were found to carry rare
CNVs that disrupt genes associated with neuronal
Table 2 Genetic characteristics of patients with absence epilepsy with recurrent risk factor or rare potential risk factor CNVs
Patient ID (sex)
Absence
epilepsy CNV coordinates (hg19/B37); cytoband Size (kb) and type UCSC gene contenta
Cases with recurrent risk
factor CNVs
C382 (F) JAE chr1:0-914,659; 1p36.33 914, Dup OR4F5, OR4F29 SAMD11, NOC2L, KLHL17,
PLEKHN1, PERM1
361202 (M) CAE chr1:146,295,308-147,826,789; 1q21.1 1531, Del LOC100288142, PRKAB2, PDIA3P, GJA5,
GJA8 (17 others)
C626 (F) JAE chr15:21,903,815-23,103,405; 15q11.2 1199, Del CXADRP2, POTEB, OR4M2, OR4N4 (17 others
including NIPA2)
chr15:31,991,226-32,567,234; 15q13.3 576, Dup CHRNA7
chrX:6,457,553-8,123,447; Xp22.31 1666, Dup HDHD1, STS, VCX, PNPLA, VCX2
371201 (F) CAE chr15:21,903,815-23,103,405; 15q11.2 1199, Dup As above
367202 (F) UAE chr15:21,903,815-23,103,405; 15q11.2 1199, Del As above
C485 (F) CAE chr22:21,803,945-24,654,974; 22q11.21-
q11.23
2851, Dup HIC2, TMEM191C, PI4KAP2, UBE2L3, YDJC
(1 42 others)
C215 (M) CAE chr15:22,522,310-23,249,493; 15q11.2 727, Del GOLGA8DP, GOLGA6L1, TUBGCP5, CYFIP1,
NIPA2, NIPA1
C457 (F) CAE chrX:6,449,682-8,138,035; Xp22.31 1688, Del VCX3A, HDHD1, STS, VCX, PNPLA, VCX2
Cases with potential risk
factor CNVs
424004 (F) UAE chr1:240,509,364-240,536,152; 1q43 26, Dup FMN2
C516 (M) JAE chr4:20,979,028-21,177,688; 4p15.32 199. Del KCNIP4
667201 (M) CAE chr4:183,599,915-184,966,267; 4q35.1 1366, Dup TENM3, DCTD, FAM92A1P2, WWC2-AS2,
WWC2 (17 others)
369201 (F) CAE chr5:75,611,865-75,640,024; 5q13.3 28, Dup SV2C
341203 (F) UAE chr6:38,360,355-38,455,141; 6p21.2 95, Del BTBD9
357201 (M) UAE chr7:37,703,928-39,432,281; 7p14.1 1728, Del GPR141, NME8, SFRP4, EPDR1, STARD3NL
(15 others including AMPH)
chr3:96,735,452-97,332,506; 3q11.2 597, Del EPHA6
397201 (M) CAE chr9:12,418,777-13,258,831; 9p23 840, Dup TYRP1, LURAP1L, MPDZ
C329 (M) CAE chr9:87,412,328-88,425,972; 9q21.33 1013, Dup NTRK2, AGTPBP1
C8 (F) UAE chr10:56,195,290-56,465,459; 10q21.1 270, Del PCDH15
717201 (F) CAE chr11:93,772,465-93,903,781; 11q21 131, Dup HEPHL1, PANX1
C72 (M) UAE chr14:103,402,254-103,462,143; 14q32.3 60, Del CDC42BPB
349201 (M) CAE chr16:77,768,588-78,186,513; 16q23.1 417, Del NUDT7, VAT1L, CLEC3A, WWOX
C454 (M) JAE chr16:78,404,208-78,431,974; 16q23.1 27, Del WWOX
C451 (M) CAE chr20:12,662,517-14,147,317; 20p12.1 1484, Dup SPTLC3, ISM1, TASP1, ESF1, NDUFAF5,
SEL1L2, MACROD2
830201 (F) CAE chrX:70,026,229-71,094,940; Xq13.1 1069, Del TEX11, SLC7A3, SNX12, FOXO4 (113 others
including NLGN3, GJB1)
Abbreviations: CAE 5 childhood absence epilepsy; CNV 5 copy number variation; Del 5 deletion; Dup 5 duplication; JAE 5 juvenile absence epilepsy;
UAE 5 unclassified absence epilepsy.
Eight patients with absence epilepsy carry 10 recurrent CNVs classified as risk factors for their epilepsy, and 15 patients carry CNVs classified as
potential risk factors.
a Boldface indicates candidate gene.
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development and function (tables 1 and 2). One
patient with UAE carries 2 of these CNVs. Although
the numbers are too small to make population-level
inference, it seems that the patients with UAE are
more likely to have a CNV in this category than are
the patients with JAE and CAE (5/23 UAE, 2/22
JAE, and 8/91 CAE). The assumption of potential
pathogenicity is detailed in the Methods section. Of
these 15 patients, 4 patients with CAE and 1 patient
with UAE carry large novel CNVs of .1 Mb in size.
The other 11 CNVs range from 26 to 840 kb. For
patients with multigene CNVs, several genes may con-
tribute to the phenotype, depending on the function.
Four categories of protein are each disrupted by sev-
eral CNVs: synaptic vesicle membrane or vesicle endocy-
tosis (GO:0030672/GO:1900242), synaptic cell
adhesion (GO:0007155), synapse organization and neu-
ronal migration via actin (actin binding GO:0003779
and actin cytoskeletal reorganization GO:0031532),
and gap junctions (GO:0005921); these are shared
across the AE subtypes. We also report 2 individuals
with CAE (C454 and 349201) and deletions disrupting
the WW domain-containing oxidoreductase (WWOX),
known to cause epilepsy, cerebellar ataxia, and mental
retardation (MR) as well as infantile epileptic
encephalopathies.17
In 2 individuals with UAE, genes involved with
synaptic vesicles are disrupted: the vesicle surface pro-
tein amphiphysin 1 (AMPH) (357201) and BTBD9,
which controls vesicle recycling (341203). SV2C,
encoding synaptic vesicle glycoprotein 2C, is also dis-
rupted in individual 369201 with CAE.
Synaptic cell adhesion genes are disrupted by CNVs
in 4 individuals: 2 with CAE and 2 with UAE. Individ-
ual 830201 with CAE carries a large novel deletion of
17 genes, including NLGN3 (neuroligin3), a postsyn-
aptic cell adhesion molecule; individual 357201 with
UAE (also with the AMPH deletion described above)
has a breakpoint within the Eph receptor tyrosine
kinase EPHA6, signaling through which neuronal
adhesion and development are regulated. TENM3,
encoding a teneurin transmembrane protein that pro-
motes cell adhesion, is disrupted by a duplication
breakpoint in patient 667201 with CAE. Lastly, 3
exons of the protocadherin PCDH15 are deleted in
C8 with UAE.
Several AE CNVs reported in this study also dis-
rupt proteins that act to organize the synapse or pro-
mote neuronal migration via interactions with the
actin cytoskeleton: the serine/threonine protein
kinase CDC42BPB (C72, UAE), FMN2 encoding
formin 2 (424004, UAE), and MPDZ (previously
MUPP1), which contains multiple protein interac-
tion PDZ domains for controlling large synaptic com-
plexes (397201, CAE). EPHA6, mentioned above,
also regulates cell–matrix interactions and migration,
which indicates the complex interplay between these
pathways.
Two patients with CAE carry disrupted gap junction
genes: GJB1, encoding CX32 (830201), a brain and
peripheral myelin connexin family member, and
PANX1, encoding Pannexin1. Of note, the hotspot
deletion at 1q21.1 in individual 361202 also contains
2 further connexin gap junction genes,GJA5 andGJA8,
although they seem not to be expressed in neurons.
CNVs in the final 3 patients, although disrupting
genes that have known functions in neuronal devel-
opment and activity, do not share common features
with the others. Individual C451 with CAE has a
1.5-kb duplication of 7 genes at 20p12.7, including
a breakpoint inMACROD2, an enzyme that removes
ADP-ribose from proteins and a well-known risk fac-
tor for autistic traits.18 The potassium channel inter-
acting protein gene KCNIP4 is disrupted by a
deletion breakpoint in JAE patient C516. Lastly,
C329, diagnosed with CAE, carries a duplication
with a breakpoint in NTRK2 (previously TRKB), a
neurotrophic tyrosine kinase receptor and brain-
derived neurotrophic factor (BDNF) receptor.
DISCUSSION The genetic basis of the AEs is com-
plex, with individuals carrying different patterns of
genetic variants that determine their risk for seizures,
some of which may be shared between the different
types of epilepsy.3 Even in large families, it is difficult
to establish genotype–phenotype relationships because
different members may carry the same genetic variants
but have different phenotypic manifestations of AE.
The search for susceptibility variants has now moved
to whole-genome studies of CNV, epigenetic analysis,
and genome sequencing.
Recurrent deletions at 15q11.2, 15q13.3, and
16p13.11 are consistently identified rare risk factors
for GGEs including AEs,7 and indeed, we found 3
deletions at 15q11.2 in our cohort. We also noted a
microduplication within the 15q13.3 hotspot of the
candidate gene CHRNA7 in a patient also carrying a
15q11.2 deletion. Although deletions at 15q11.2 are
robustly associated with GGEs and developmental dis-
orders, duplications at this locus, seen in 1 patient in
our cohort, were initially reported as variants of
unknown significance. However, more recent studies
of the region indicate that mild intellectual disability
(ID), autism, and seizures are common features in in-
dividuals carrying these duplications,19 providing some
evidence that this CNV may be a risk factor for the
epilepsy in the individual described here. We also
uncovered CNVs that are more commonly recorded
in other neurodevelopmental disorders at 4 further
recurrent regions. Only 1 patient with JAE and none
with CAE have been previously reported with the
1q21.1 deletion.20 The deletion leads to a variable
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phenotype, and seizures are seen infrequently, indicat-
ing the novelty of this region in a patient with CAE.
We also identified 1 deletion and 1 duplication at
Xp22.31, previously associated with MR and ichthyo-
sis. Although seizures are now becoming a more widely
reported phenotype,21 absence seizures are not.
22q11.2 duplication syndrome has a variable pheno-
type, with MR and motor delay being the most com-
mon features. Seizures are reported rarely but are not
well described apart from a recent case with continuous
spikes and waves during sleep.22 Lastly, we observed a
914-kb duplication of the distal end of Chr1
(1p36.33), which included the infantile spasm candi-
date KLHL17.16 Duplications of 1p36.3 are less fre-
quently recorded, are of variable size, and include
developmental delay, seizures, and hypotonia with
wide phenotypic heterogeneity and an overall “milder”
phenotype than the reciprocal deletions.23 It may be
that the smaller number of duplicated genes in the
patient described here, including KLHL17, could pre-
dispose to her JAE, but it is difficult to ascribe patho-
genicity in such an isolated case. It seems from previous
large-scale studies of the GGEs that variation at these
recurrent regions is indeed rare within the AEs, but
targeted studies in more patients could help to
resolve this.
The identification of 2 patients with CAE with de-
letions that disrupt coding regions ofWWOX, known
to cause infantile epileptic encephalopathies as well as
epilepsy, cerebellar ataxia, and MR, is intriguing.17
These severe phenotypes are caused by biallelic muta-
tions or CNV within the gene. The rare heterozygous
CNVs seen here may cause the less severe syndrome
of CAE, although very rare exonic deletions (0.04%)
have been reported in the Database of Genomic Var-
iants. Screening for mutations and CNV as well as
protein function work in other patients with AE may
help to answer this question.
In this investigation we also show that patients
from all 3 subsyndromes carry rare CNVs that disrupt
genes shared largely within 4 categories of function,
involved in developing neural circuitry and at the
mature synapse. All of these CNVs are unique to
a given individual and confirm the strong genetic het-
erogeneity in the AEs.
Synaptic vesicles store and move neurotransmit-
ters for release at the presynaptic membrane, and sev-
eral proteins involved in vesicle release and recycling
have been related directly to epileptogenesis24 and
are also enriched in CNVs from patients with infan-
tile spasms.16 In our investigation we identified 3
individuals with disrupted synaptic vesicle genes:
AMPH, SV2C, and BTBD9. AMPH is involved in
neuronal transmission and development through
clathrin-mediated endocytosis of synaptic vesicles.
Amphiphysin 1 is also a substrate for CDKL5, a
kinase associated with neurodevelopmental disorders
such as X-linked West (infantile spasms) syndrome
and Rett syndrome.25 SV2C acts via presynaptic cal-
cium to regulate neurotransmitter release from
vesicles in glutamatergic synapses. SV2C shows
altered brain expression patterns in patients with tem-
poral lobe epilepsy,26 and all 3 SV2 family members
(A, B, and C) are candidates for epilepsy.27 Lastly,
BTBD9, a gene associated with restless legs syndrome
and Tourette syndrome, may regulate synaptic plas-
ticity via altered synaptic vesicle recycling.28
Several mechanisms believed to contribute to epi-
leptogenesis are likely to be regulated by cell adhesion,
such as the dysregulation of GABAergic transmission,
the guidance of axonal growth, and the stabilization
of synaptic contacts and long-term potentiation
(LTP).29 Synaptic cell adhesion genes PCDH15,
NLNG3, TENM3, and EPHA6 are disrupted by
CNV in our study. The protocadherin PCDH15 me-
diates the formation, maturation, and specification of
synapses and is a determinant of brain serotonin trans-
porter expression.30 Mutations of PCDH15 are known
to cause Usher syndrome 1F, in which ID and psychi-
atric disturbances are common, and deletions are
found in patients with epileptic encephalopathies.31
The family member PCDH19 also causes X-linked
infantile epileptic encephalopathy.32 The postsynaptic
cell adhesion molecule NLGN3 functions in synapto-
genesis and neuron–glia communications and is a can-
didate for autism with comorbid epilepsy, in which it
may influence seizure susceptibility.33 The teneurin
member TENM3 promotes cell adhesion and synaptic
organization, similar to the role of neuroligins, and
may also regulate excitatory synaptic strength via latro-
philin binding.34 Lastly, the Eph receptor tyrosine
kinase EPHA6 also regulates neuronal cell adhesion,
cell–matrix interactions (below), and migration, with
clear roles in modulating synapse formation and plas-
ticity and axon guidance.35
A third category of genes that are disrupted in 3 pa-
tients with AE are those that organize the synapse and
neuronal migration via the actin cytoskeleton. MPDZ
controls large complexes at the synapse and is involved
in learning- and memory-related synaptic plasticity. Its
dysfunction has pleiotropic effects on vulnerability to
seizures through interactions with many types of syn-
aptic receptors.36 The kinase CDC42BPB regulates
cytoskeletal remodeling and cell migration37 and is
involved in hippocampal LTP. Lastly, FMN2mediates
synaptic spine density and is highly expressed in the
developing brain. FMN2mutations can cause nonsyn-
dromic ID.38
Gap junctions, both between dendrites and
between axons and glia, are highly implicated in syn-
chronous seizure activity, and blocking communica-
tion at gap junctions is anticonvulsant.39 Two gap
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junction proteins disrupted here, connexin Cxs32
(encoded by GJB1) and Pannexin1 (encoded by
PANX1), are good AE candidates. Mutations in
GJB1 cause X-linked Charcot-Marie-Tooth disease,
with some patients also showing CNS symptoms.40
Cxs32 expression is also altered in the hippocampi of
patients with mesial temporal lobe epilepsy.41 Pan-
nexin1 is upregulated in epileptic brain tissue and
may contribute to seizures by increasing the levels
of extracellular ATP. Targeting Pannexin1 improves
seizure outcome in animal models.42
Other GOIs that were disrupted by rare CNVs in
patients with AE include NTRK2, a BDNF receptor
that modulates excitatory transmission, synaptic plas-
ticity, and hippocampal LTP and is required for epi-
leptogenesis in animal models.43 Patients with mesial
temporal lobe epilepsy show altered NTRK2 expres-
sion,44 and dysregulated NTRK2-BDNF signaling is
implicated in several neurodevelopmental disorders,
indicating its excellent candidacy for AE. The potassi-
um channel interacting protein gene KCNIP4, deleted
in a patient with JAE, forms part of a negative feedback
loop in theWnt/b-catenin pathway that regulates neu-
ronal development and is a candidate for attention-
deficit/hyperactivity disorder.45 Lastly, the autism risk
factor geneMACROD2 was also disrupted in a patient
with CAE.18
A major limitation of our study is that it is a retro-
spective analysis of cohorts collected for previous
genetic studies of AEs. This meant that we did not
have useable DNA from family members to assess
the inheritance of the CNVs and we were not able
to recontact the families for collection of new DNA.
Analysis of CNV inheritance would have aided in
our putative assignment of pathogenicity to the CNVs,
as those that were inherited with the disorder, or de no-
vo in the probands, would be more likely to predispose
to the epilepsy. We were also unable to access the orig-
inal EEGs and the MRI reports of some patients,
which would have allowed us to provide more detailed
phenotypes in table 1. However, patients’ diagnoses
were ascertained both through the clinical services
from which they were recruited and by experts in
childhood epilepsies collating the cohorts for the initial
studies; we therefore believe that other diagnoses have
been sufficiently excluded, and further classification
based on available data for our cohort is robust.
Our study of CNV across the spectrum of AEs has
reinforced both the complex and heterogeneous nature
of these disorders and their potential for shared genetic
mechanisms. We have strengthened the evidence for
the role of recurrent CNVs and added AEs as disorders
potentially associated with CNV at 1q21.1 and
Xp22.31. Through the study of rare CNV, we indicate
pathways that may be disrupted across AE subtypes
and open the door for investigations of neural network
behavior in future large-scale studies of broad category
patients with AE and their families. This, as well as
functional work of the disrupted genes, will help in
understanding the role of these potential new pathways
in seizure generation.
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